Review waiting, please be patient. This may take 3 months or more, since drafts are reviewed in no specific order. There are 4,358 pending submissions waiting for review. If the submission is accepted, then this page will be moved into the article space. If the submission is declined, then the reason will be posted here. In the meantime, you can continue to improve this submission by editing normally. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Easy tools: Citation bot (help) | Advanced: Fix bare URLs Reviewer tools Instructions · What links here · Fulgent Genetics (talk: + · bio) · (log) · Copyvios report · reFill · Citation Bot · (Search: Google, Wikipedia) · Submitted 52 days ago by Feijun0104 (talk: D · +) · Last edited 32 days ago by Snowman304

Submission declined on 26 February 2026 by SnowyRiver28 (talk). This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for organizations and companies. The draft requires multiple published secondary sources that: provide significant coverage: discuss the subject in detail, excluding routine coverage like product launches, staff appointments, or financial reports and listings in databases or listicles; are reliable: from reputable outlets with editorial oversight; are independent: not connected to the subject, such as press releases, the subject's own website, or sponsored content. Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia. This draft reads like an essay or opinion piece. Wikipedia is not a place for original research or personal opinions. The draft should: summarize secondary sources: do not offer your own analysis or arguments; be written from a neutral point of view: represent the subject without bias, avoiding praise, criticism, or persuasive or promotional language; not contain original research: do not include new theories, unpublished ideas, or personal experiences. Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. If you would like to continue working on the submission, click on the "Edit" tab at the top of the window. If you have not resolved the issues listed above, your draft will be declined again and potentially deleted. If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors. Please do not remove reviewer comments or this notice until the submission is accepted. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Easy tools: Citation bot (help) | Advanced: Fix bare URLs Declined by SnowyRiver28 3 months ago. Last edited by Snowman304 32 days ago. Reviewer: Inform author. This draft has been resubmitted and is currently awaiting re-review.

• Comment: The sources are Fulgent's websites, press releases, sponsored content, or clinical study data presumably provided by Fulgent.

Fulgent Genetics is a genomic testing company headquartered in El Monte, California with multiple CLIA-certified and CAP-accredited laboratories in the United States.^[1] Its laboratories mainly perform genetic testing and oncology diagnostic services for clinical clients, including services for oncology, anatomic pathology, rare disease, and reproductive health.

The company also has a therapeutic development business line, Fulgent Pharma, through which they are developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform.^[2]

The company was initially founded as Fulgent Therapeutics by Ming Hsieh and James Xie (previously of Cogent Systems) with an initial focus on cancer therapeutics.^{[citation needed]} The founders’ focus shifted to genetic testing via next-generation sequencing (NGS) with the arrival of Dr. Harry Gao (previously of City of Hope) in 2012.

In 2014, Fulgent Genetics became the first clinical laboratory to offer copy number variation detection using NGS technology in the United States. While their test offerings began with pediatric rare disease NGS analysis, at this time they began to expand to include genetic tests for a variety of medical disciplines, including reproductive medicine, oncology, cardiology, neurology, and others.

In September 2016, Fulgent became a public company via an initial public offering on the NASDAQ exchange.^[3] In the following years the company continued to expand its genetic testing menu to include over 10,000 genes and over 170 genetic testing panels.

In 2019, Fulgent launched an at-home testing line called Picture Genetics, a service offering clinical-grade, at-home genetic tests for cancer and cardio risk assessment, carrier screening, and newborn screening.^[4] Also in 2019, the company announced a collaboration with the Parkinson's Foundation on a new genetic testing initiative for individuals living with Parkinson's Disease.^[5]

Fulgent launched COVID-19 testing in May 2020 by using their genetic testing resources to validate and perform viral RNA sequencing. Existing technology platforms allowed the company to expand testing rapidly, and it received FDA Emergency Use Authorization (EUA) for RT-PCR COVID-19 testing later that year.^[6][7] After receiving this authorization, Fulgent went on to provide contracted testing services to a variety of states, counties, and school systems.^{[8][9][10][11][12][13] [14]} The company was also awarded a CDC contract in 2021 to study COVID-19 variants.^[15]

In August 2021, Fulgent acquired CSI Laboratories, expanding the company's capabilities in molecular diagnostics and oncologic testing, including flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization (“FISH”), immunohistochemistry, and molecular genetics.^[16]

Fulgent went on to acquire Inform Diagnostics in April 2022, allowing the expansion of its test menu into anatomic pathology, including the subspecialties of breast pathology, gastrointestinal pathology, dermatopathology, urologic pathology, neuropathology, and hematopathology.^[17] The acquisitions of both CSI Laboratories and Inform Diagnostics led to the integration of Fulgent Oncology, a line of business specializing in testing for clinical oncologists and pathologists.^[18]

In November 2022, Fulgent acquired Fulgent Pharma Holdings, Inc. (“Fulgent Pharma”), a venture previously started by Fulgent's founders to develop anti-cancer therapies using nanoencapsulation techniques. Fulgent Pharma had previously split from Fulgent Genetics as an entity in 2016, when the businesses were separated ahead of the Initial Public Offering of Fulgent Genetics, but was re-acquired to help achieve the company's goal of providing comprehensive cancer care solutions.^[19]

In August 2025, Fulgent acquired ANP Technologies under Fulgent Pharma to further expand its therapeutics IP portfolio.^{[citation needed]}

The company offers over 18,000 single gene tests and over 900 rare disease tests, as well as whole genome sequencing, mitochondrial sequencing, and reproductive health tests.^[20] The latter include Beacon Carrier Screening, a suite of panels designed to detect risk for early-onset conditions in an individual or reproductive pair's offspring,^[21] and KNOVA Prenatal Cell-Free DNA Screening, a non-invasive prenatal test that helps identify risk for certain genetic conditions in a baby by analyzing blood from a pregnant patient.^[22]

This section does not cite any sources. Please help improve this section by adding citations to reliable sources. Unsourced material may be challenged and removed. (Learn how and when to remove this message)

Fulgent's Oncology somatic genetic testing services include the Lumera™ product line, which offer full genomic profiles of solid tumor tissue as well as hematological evaluations. Fulgent Oncology also offers germline cancer testing, pharmacogenetic testing, and specialty pathology services including immunohistochemistry, flow cytometry, cytogenetics, and fluorescent in situ hybridization (FISH).

The company's BioPharma Services team provides Fulgent's technology and expertise to academic and pharmacological teams in need of such services for their research. These services are offered globally and include next-generation sequencing, various pathology services, and other customizable services including multiplex immunofluorescence and Olink Proteomics.^[23]

Fulgent Pharma, which operated as an independent entity from 2016 but was reacquired by Fulgent in 2022, is a clinical stage pharmaceutical company focused on developing and commercializing cancer therapeutics.^[24] Currently they have two drugs in the clinical trial phase: FID-007 has been approved for phase II of clinical trials as of February 2024,^[25] and FID-022 has been approved for phase I of clinical trials as of January 2025.^[26]

Picture Genetics is a service offered by Fulgent that provides clinician-supported genetic testing that consumers can order from home, receiving saliva collection kits in the mail and reports delivered online.^[27] Available tests include Picture Parenting, a carrier screening test to help identify one's risk of passing on a genetic condition to their children; Picture Wellness, which can identify genetics-related lifetime risk for certain cancers and cardiovascular conditions in adults; Picture Newborn, which screens for rare, early-onset disorders in children for which early detection could improve the child's life; Picture PGx, which provides genetic insight on a person's ability to process various medications; and Picture PD Aware, which helps assess one's risk for developing Parkinson's Disease.^[28]